Given the role that cyclin D:CDK4/6 plays in cell cycle reentry from senescence (Fig 6E and F), it is conceivable that sequential treatment with a DNA‐damaging agent followed by an FDA‐approved CDK4/6 inhibitor such as palbociclib might help reduce tumor recurrence. Here, CDK4 is linked to neoplasm.